Miranda M, Marí M, Ardite E, Morales A. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997; 273: G7-G17 14 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. <strong>Gastroenterology</strong> <strong>20</strong>00; 119: 1637-1648 15 Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial <strong>of</strong> infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology <strong>20</strong>04; 39: 1390-1397 16 Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebocontrolled multicenter trial <strong>of</strong> etanercept in the treatment <strong>of</strong> alcoholic hepatitis. <strong>Gastroenterology</strong> <strong>20</strong>08; 135: 1953-1960 17 Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial <strong>of</strong> vitamin E for alcoholic hepatitis. J Hepatol <strong>20</strong>04; 40: 40-46 18 Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. A randomized trial <strong>of</strong> antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol <strong>20</strong>07; 47: 277-283 19 Wright C, Moore RD. Disulfiram treatment <strong>of</strong> alcoholism. Am J Med 1990; 88: 647-655 <strong>20</strong> Cvek B, Dvorak Z. The value <strong>of</strong> proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today <strong>20</strong>08; 13: 716-722 21 Wickström M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, Larsson R, Lövborg H. Pharmacological pr<strong>of</strong>iling <strong>of</strong> disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol <strong>20</strong>07; 73: 25-33 22 Naujokat C, Berges C, Höh A, Wieczorek H, Fuchs D, Ovens J, Miltz M, Sadeghi M, Opelz G, Daniel V. Proteasomal chymotrypsin-like peptidase activity is required for essential functions <strong>of</strong> human monocyte-derived dendritic cells. Immunology <strong>20</strong>07; 1<strong>20</strong>: 1<strong>20</strong>-132 23 Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta <strong>20</strong>04; 1695: 225-233 24 Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, Schmidt-Ullrich R, Steinh<strong>of</strong>f U. Proteasome-mediated degradation <strong>of</strong> IkappaBalpha and processing <strong>of</strong> p105 in Crohn disease and ulcerative colitis. J Clin Invest <strong>20</strong>06; 116: 3195-3<strong>20</strong>3 25 Groll M, Huber R, Moroder L. The persisting challenge <strong>of</strong> selective and specific proteasome inhibition. J Pept Sci <strong>20</strong>09; 15: 58-66 26 Gilardini A, Marmiroli P, Cavaletti G. Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem <strong>20</strong>08; 15: 3025-3035 27 Chauhan D, Bianchi G, Anderson KC. Targeting the UPS as therapy in multiple myeloma. BMC Biochem <strong>20</strong>08; 9 Suppl 1: S1 28 Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study <strong>of</strong> bortezomib in relapsed, refractory myeloma. N Engl J Med <strong>20</strong>03; 348: 2609-2617 29 Dou QP, Goldfarb RH. Bortezomib (millennium pharmaceuticals). IDrugs <strong>20</strong>02; 5: 828-834 30 Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial <strong>of</strong> PS-341 in patients with renal cell cancer: a University <strong>of</strong> Chicago phase II consortium study. J Clin Oncol <strong>20</strong>04; 22: 115-119 31 Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, WJG|www.wjgnet.com Bardag-Gorce F. Proteasome inhibitor and oxidative stress Russo P, Mazumdar M, Motzer RJ. Phase II trial <strong>of</strong> bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol <strong>20</strong>04; 22: 37<strong>20</strong>-3725 32 Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M. Phase II study <strong>of</strong> the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res <strong>20</strong>04; 10: 6111-6118 33 Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial <strong>of</strong> the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol <strong>20</strong>04; 22: 2108-2121 34 Jung T, Engels M, Kaiser B, Poppek D, Grune T. Intracellular distribution <strong>of</strong> oxidized proteins and proteasome in HT22 cells during oxidative stress. Free Radic Biol Med <strong>20</strong>06; 40: 1303-1312 35 Kelly SM, Vanslyke JK, Musil LS. Regulation <strong>of</strong> ubiquitinproteasome system mediated degradation by cytosolic stress. Mol Biol Cell <strong>20</strong>07; 18: 4279-4291 36 Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, Akaike A. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem <strong>20</strong>07; 282: 4364-4372 37 Williams AJ, Dave JR, Tortella FC. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int <strong>20</strong>06; 49: 106-112 38 Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia <strong>20</strong>07; 21: 30-36 39 Lorenz M, Wilck N, Meiners S, Ludwig A, Baumann G, Stangl K, Stangl V. Proteasome inhibition prevents experimentally-induced endothelial dysfunction. Life Sci <strong>20</strong>09; 84: 929-934 40 Donohue TM, Cederbaum AI, French SW, Barve S, Gao B, Osna NA. Role <strong>of</strong> the proteasome in ethanol-induced liver pathology. Alcohol Clin Exp Res <strong>20</strong>07; 31: 1446-1459 41 French SW. Intragastric ethanol infusion model for cellular and molecular studies <strong>of</strong> alcoholic liver disease. J Biomed Sci <strong>20</strong>01; 8: <strong>20</strong>-27 42 Preedy VR, Adachi J, Asano M, Koll M, Mantle D, Niemela O, Parkkila S, Paice AG, Peters T, Rajendram R, Seitz H, Ueno Y, Worrall S. Free radicals in alcoholic myopathy: indices <strong>of</strong> damage and preventive studies. Free Radic Biol Med <strong>20</strong>02; 32: 683-687 43 Gouillon Z, Lucas D, Li J, Hagbjork AL, French BA, Fu P, Fang C, Ingelman-Sundberg M, Donohue TM, French SW. Inhibition <strong>of</strong> ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med <strong>20</strong>00; 224: 302-308 44 Bousquet-Dubouch MP, Nguen S, Bouyssié D, Burlet- Schiltz O, French SW, Monsarrat B, Bardag-Gorce F. Chronic ethanol feeding affects proteasome-interacting proteins. Proteomics <strong>20</strong>09; 9: 3609-3622 45 Oliva J, Dedes J, Li J, French SW, Bardag-Gorce F. Epigenetics <strong>of</strong> proteasome inhibition in the liver <strong>of</strong> rats fed ethanol chronically. <strong>World</strong> J Gastroenterol <strong>20</strong>09; 15: 705-712 46 Zeng T, Zhang CL, Zhu ZP, Yu LH, Zhao XL, Xie KQ. Diallyl trisulfide (DATS) effectively attenuated oxidative stressmediated liver injury and hepatic mitochondrial dysfunction in acute ethanol-exposed mice. Toxicology <strong>20</strong>08; 252: 86-91 47 Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci <strong>20</strong>07; 81: 177-187 48 Bardag-Gorce F, Oliva J, Lin A, Li J, French BA, French SW. Proteasome inhibitor up regulates liver antioxidative en- 2561 May 28, <strong>20</strong>11|Volume 17|Issue <strong>20</strong>|
Bardag-Gorce F. Proteasome inhibitor and oxidative stress zymes in rat model <strong>of</strong> alcoholic liver disease. Exp Mol Pathol <strong>20</strong>11; 90: 123-130 49 Meiners S, Ludwig A, Lorenz M, Dreger H, Baumann G, Stangl V, Stangl K. Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med <strong>20</strong>06; 40: 2232-2241 50 Bardag-Gorce F, Vu J, Nan L, Riley N, Li J, French SW. Proteasome inhibition induces cytokeratin accumulation in vivo. Exp Mol Pathol <strong>20</strong>04; 76: 83-89 WJG|www.wjgnet.com 51 Oliva J, Lin A, Li J, French BA, French SW, Bardag-Gorce F. Proteasome inhibitor treatment reduces hepatic steatosis by decreasing lipogenic enzymes gene expression. The 33rd Annual RSA Scientific Meeting; <strong>20</strong>10 Jun 26-30; San Antonio, Texas, USA. Alcoholism: Clinical Experimental Research, <strong>20</strong>10: 87A, Abstract #308 52 Bardag-Gorce F, Oliva J, Li A, Li J, French SW. The beneficial effects <strong>of</strong> proteasome inhibitor treatment in alcoholic liver disease. FASEB J <strong>20</strong>11; 25: 366.9 S- Editor Tian L L- Editor Webster JR E- Editor Zheng XM 2562 May 28, <strong>20</strong>11|Volume 17|Issue <strong>20</strong>|
- Page 1 and 2:
World Journal of Gastroenterology W
- Page 3 and 4:
Robert JL Fraser, Daw Park Jacob Ge
- Page 5 and 6:
Italy Donato F Altomare, Bari Piero
- Page 7 and 8:
Fernando Azpiroz, Barcelona Ramon B
- Page 9 and 10:
S Contents EDITORIAL TOPIC HIGHLIGH
- Page 11 and 12:
Contents APPENDIX FLYLEAF EDITORS F
- Page 13:
Online Submissions: http://www.wjgn
- Page 17 and 18:
Mandrekar P. Epigenetics and alcoho
- Page 19 and 20:
Mandrekar P. Epigenetics and alcoho
- Page 21 and 22:
Mandrekar P. Epigenetics and alcoho
- Page 23 and 24:
Moghe A et al . Altered nutrients,
- Page 25:
Moghe A et al . Altered nutrients,
- Page 28 and 29:
James SJ. Intracellular S-adenosylh
- Page 36 and 37:
Pathol 2008; 214: 199-210 14 Alexak
- Page 38 and 39:
69: 562-573 91 Murphy FR, Issa R, Z
- Page 45:
Aziz-Seible RS et al . Fibronectin
- Page 48 and 49:
mechanisms accounted for by autoimm
- Page 50 and 51:
extensively used in alcohol researc
- Page 52 and 53:
to autocrine TNF-a signaling after
- Page 54 and 55:
Sondek J, Zuobi-Hasona K, Aukhil I.
- Page 56 and 57:
stress in alcohol toxicity. Free Ra
- Page 58 and 59:
HIV, VIRAL HEPATITIS AND ALCOHOL US
- Page 60 and 61:
Table 1 Common mechanisms of liver/
- Page 62 and 63:
perpermeability and endotoxemia pri
- Page 64:
Online Submissions: http://www.wjgn
- Page 70 and 71: metabolism. Nature 2009; 458: 1131-
- Page 72: Online Submissions: http://www.wjgn
- Page 75 and 76: Mercer DF. Hepatitis and alcohol ef
- Page 77 and 78: Online Submissions: http://www.wjgn
- Page 79 and 80: Dolganiuc A. Role of lipid rafts in
- Page 83 and 84: Dolganiuc A. Role of lipid rafts in
- Page 85 and 86: Dolganiuc A. Role of lipid rafts in
- Page 87 and 88: Dolganiuc A. Role of lipid rafts in
- Page 89 and 90: Dolganiuc A. Role of lipid rafts in
- Page 91 and 92: Dolganiuc A. Role of lipid rafts in
- Page 93 and 94: Online Submissions: http://www.wjgn
- Page 95: Lakner AM et al . microRNAs and liv
- Page 99 and 100: Lakner AM et al . microRNAs and liv
- Page 102 and 103: in alcoholic liver steatosis [39,40
- Page 105 and 106: Suh YG et al . HSCs and innate immu
- Page 107 and 108: Suh YG et al . HSCs and innate immu
- Page 109 and 110: Online Submissions: http://www.wjgn
- Page 111 and 112: Schaffert CS et al . MGST1: Friend
- Page 113 and 114: Schaffert CS et al . MGST1: Friend
- Page 115 and 116: Online Submissions: http://www.wjgn
- Page 117: Bardag-Gorce F. Proteasome inhibito
- Page 121 and 122: Oh BY et al . siRNA therapy in colo
- Page 123 and 124: A Livin expression (%) 120 100 80 6
- Page 125: Tumor volume (cm 3 ) Oh BY et al .
- Page 128 and 129: M, Coggi G, Bosari S. Inhibitors of
- Page 130 and 131: Institute, UPMC Montefiore, 7 South
- Page 132 and 133: A B C D E Figure 1 Change in coloni
- Page 135 and 136: Jiang HP et al . Differential prote
- Page 137 and 138: Online Submissions: http://www.wjgn
- Page 139 and 140: A B C Vespasiani Gentilucci U et al
- Page 141 and 142: Vespasiani Gentilucci U et al . Non
- Page 143 and 144: Online Submissions: http://www.wjgn
- Page 145 and 146: Instructions to authors ISSN and EI
- Page 147 and 148: Instructions to authors used rather
- Page 149: Instructions to authors Chaoyang Di
Change language